AstraZeneca (NASDAQ:AZN) Given "Buy (B)" Rating at Weiss Ratings

Key Points

• AstraZeneca's stock has been reaffirmed with a "Buy (B)" rating by Weiss Ratings, while other analysts have mixed views with four rating it as a Buy and one as a Sell.
• The company's shares recently traded at $83.29 after a slight decline, with a 52-week high of $86.57 and a low of $61.24.
• AstraZeneca reported a 16.1% increase in revenue year-over-year, totaling $14.46 billion for the quarter, meeting EPS expectations of $1.09.

AstraZeneca (NASDAQ:AZN - Get Free Report)'s stock had its "buy (b)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

Other equities analysts also recently issued reports about the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a "hold" rating to a "sell" rating in a research report on Thursday, October 16th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $86.00.

AstraZeneca Stock Down 0.1%

Shares of NASDAQ:AZN traded down $0.11 on Friday, reaching $83.29. The company had a trading volume of 2,380,329 shares, compared to its average volume of 5,167,490. AstraZeneca has a 52-week low of $61.24 and a 52-week high of $86.57. The firm's 50 day simple moving average is $80.79 and its 200-day simple moving average is $74.22. The firm has a market capitalization of $258.32 billion, a PE ratio of 31.31, a PEG ratio of 1.54 and a beta of 0.36. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. During the same period last year, the business posted $1.24 EPS. The business's revenue was up 16.1% compared to the same quarter last year. As a group, analysts expect that AstraZeneca will post 4.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AstraZeneca

Large investors have recently made changes to their positions in the stock. NewSquare Capital LLC grew its holdings in shares of AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company's stock valued at $25,000 after buying an additional 218 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after buying an additional 289 shares during the last quarter. Richardson Financial Services Inc. grew its holdings in shares of AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company's stock valued at $28,000 after buying an additional 149 shares during the last quarter. Costello Asset Management INC purchased a new stake in shares of AstraZeneca during the first quarter valued at $29,000. Finally, FSA Wealth Management LLC grew its holdings in shares of AstraZeneca by 376.0% during the second quarter. FSA Wealth Management LLC now owns 476 shares of the company's stock valued at $33,000 after buying an additional 376 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.